IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung CancerTadashi Manabe, Kenzo Soejima, Hiroyuki Yasuda et al.|Molecular Cancer Research|2020Cited by 54
Supplementary Figures S1-S6 from IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung CancerTadashi Manabe, Kenzo Soejima, Toshiki Ebisudani et al.|Unknown|2023Cited by 0
Supplementary Methods from IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung CancerTadashi Manabe, Kenzo Soejima, Hiroyuki Yasuda et al.|Unknown|2023Cited by 0
Supplementary Tables S1-S8 from IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung CancerTadashi Manabe, Kenzo Soejima, Hiroyuki Yasuda et al.|Unknown|2023Cited by 0
Supplementary Figures S1-S6 from IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung CancerTadashi Manabe, Kenzo Soejima, Hiroyuki Yasuda et al.|Unknown|2023Cited by 0